BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi QUA, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; 26(30): 4428-4441 [PMID: 32874055 DOI: 10.3748/wjg.v26.i30.4428] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Gisbert JP, Chaparro M. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)? J Clin Med 2021;10:5318. [PMID: 34830595 DOI: 10.3390/jcm10225318] [Reference Citation Analysis]
2 Saito D, Matsuura M, Ozaki R, Tokunaga S, Minowa S, Mitsui T, Miura M, Sakuraba A, Hayashida M, Miyoshi J, Hisamatsu T. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open 2021;5:1056-62. [PMID: 34584975 DOI: 10.1002/jgh3.12630] [Reference Citation Analysis]
3 Attauabi M, Madsen GR, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00856-2. [PMID: 34903497 DOI: 10.1016/j.dld.2021.11.014] [Reference Citation Analysis]
4 Eriksson C, Rundquist S, Lykiardopoulos V, Udumyan R, Karlén P, Grip O, Söderman C, Almer S, Hertervig E, Marsal J, Gunnarsson J, Malmgren C, Delin J, Strid H, Sjöberg M, Öberg D, Bergemalm D, Hjortswang H, Halfvarson J; SWIBREG SVEAH Study Group. Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therap Adv Gastroenterol 2021;14:17562848211023386. [PMID: 34276808 DOI: 10.1177/17562848211023386] [Reference Citation Analysis]
5 Attauabi M, Höglund C, Fassov J, Pedersen KB, Hansen HB, Wildt S, Jensen MD, Neumann A, Lind C, Jacobsen HA, Popa AM, Kjeldsen J, Pedersen N, Molazahi A, Haderslev K, Aalykke C, Knudsen T, Cebula W, Munkholm P, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scand J Gastroenterol 2021;56:1040-8. [PMID: 34224299 DOI: 10.1080/00365521.2021.1946588] [Reference Citation Analysis]
6 Abraham B, Glassner K. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis. Curr Opin Gastroenterol 2021;37:344-50. [PMID: 33731642 DOI: 10.1097/MOG.0000000000000738] [Reference Citation Analysis]